194 related articles for article (PubMed ID: 36523978)
21. Advances and perspectives of PARP inhibitors.
Yi M; Dong B; Qin S; Chu Q; Wu K; Luo S
Exp Hematol Oncol; 2019; 8():29. PubMed ID: 31737426
[TBL] [Abstract][Full Text] [Related]
22. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
23. RAD51-Mediated DNA Homologous Recombination Is Independent of
Sinha A; Saleh A; Endersby R; Yuan SH; Chokshi CR; Brown KR; Kuzio B; Kauppinen T; Singh SK; Baker SJ; McKinnon PJ; Katyal S
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138032
[TBL] [Abstract][Full Text] [Related]
24. Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens.
Clements KE; Schleicher EM; Thakar T; Hale A; Dhoonmoon A; Tolman NJ; Sharma A; Liang X; Imamura Kawasawa Y; Nicolae CM; Wang HG; De S; Moldovan GL
Nat Commun; 2020 Nov; 11(1):6118. PubMed ID: 33257658
[TBL] [Abstract][Full Text] [Related]
25. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
26. Homologous Recombination Repair Deficiency: An Overview for Pathologists.
Doig KD; Fellowes AP; Fox SB
Mod Pathol; 2023 Mar; 36(3):100049. PubMed ID: 36788098
[TBL] [Abstract][Full Text] [Related]
27. Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer.
Veneziani AC; Scott C; Wakefield MJ; Tinker AV; Lheureux S
Ther Adv Med Oncol; 2023; 15():17588359231157644. PubMed ID: 36872947
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmüller L
Carcinogenesis; 2014 Oct; 35(10):2273-82. PubMed ID: 25085902
[TBL] [Abstract][Full Text] [Related]
29. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Lee EK; Matulonis UA
Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
[TBL] [Abstract][Full Text] [Related]
30. PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.
McNevin CS; Cadoo K; Baird AM; Finn SP; McDermott R
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230674
[TBL] [Abstract][Full Text] [Related]
31. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
32. Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations.
Hu J; Liang P; Jin D; Fan R; Xie X; Liu C; Jiang Q; Gao L
Expert Rev Anticancer Ther; 2022 Jul; 22(7):717-723. PubMed ID: 35679134
[TBL] [Abstract][Full Text] [Related]
33. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
34. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
35. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.
Heitmann J; Geeleher P; Zuo Z; Weichselbaum RR; Vokes EE; Fetscher S; Seiwert TY
Oral Oncol; 2014 Sep; 50(9):825-31. PubMed ID: 25017803
[TBL] [Abstract][Full Text] [Related]
36. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
[TBL] [Abstract][Full Text] [Related]
37. Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
Kawanishi M; Fujita M; Karasawa K
Breast Cancer (Auckl); 2022; 16():11782234221080553. PubMed ID: 35340889
[TBL] [Abstract][Full Text] [Related]
38. Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.
Wang LM; Wang P; Chen XM; Yang H; Song SS; Song Z; Jia L; Chen HD; Bao XB; Guo N; Huan XJ; Xi Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Chen Y; Ding J; Lang JY; Miao ZH; Zhang A; He JX
EMBO Mol Med; 2023 Mar; 15(3):e16235. PubMed ID: 36652375
[TBL] [Abstract][Full Text] [Related]
39. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
40. PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.
Ito S; Murphy CG; Doubrovina E; Jasin M; Moynahan ME
PLoS One; 2016; 11(7):e0159341. PubMed ID: 27428646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]